Abstract
EU Paediatric Regulation was adopted by the European Parliament and the Council in December 2006. First meeting of the Paediatric Committee took place in July 2007. 1. Paediatric investigation Plans (PIPs) In 2007-2013 The European Medicines Agency (EMA) and its Paediatric Committee have agreed more than 600 Paediatric Investigation Plans (PIPs) with pharmaceutical companies, to provide data on the efficacy and safety of medicines for diseases of children. · For treatment of JIA PIP was agreed for the following substances: abatacept, adalimumab, anakinra, anti-BAFF antibody, anti-IL-6 antibody, anti-IL17 antibody, anti-IL-17A antibody, apremilast, baricitinib, canakinumab, certolizumab, denosumab, etanercept, givinostat, golimumab, olokizumab, sarilumab, tocilizumab, tofacitinib and ustekinumab. · For treatment of SLE in children PIP was agreed for anti-BAFF, belimumab and epratuzumab. · For treatment of CAPS PIP was agreed for anakinra, anti-IL-1beta antibody and canakinumab. 2. Clinical trials More paediatric clinical trials were done (data from EudraCT, accessible at the European Clinical Trials Register): 3. New authorised indications for children · 12/11/2009: canakinumab for treatment of CAPS. · 25/08/2008: adalimumab - treatment of active polyarticular juvenile idiopathic arthritis in adolescents from 13 to 17 years of age. · 20/01/2010 abatacept - treatment of moderate to severe active polyarticular juvenile idiopathic arthritis in paediatric patients 6 years of age and older. · 18/03/2011 adalimumab - treatment of active polyarticular juvenile idiopathic arthritis in the paediatric population aged from 4 to 12 years. · 01/08/2011: tocilizumab - treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 2 years of age and older. · 24/08/2011: etanercept - polyarticular juvenile idiopathic arthritis (JIA) from the age of 2 years. · 24/08/2012: etanercept - treatment of RF+ and RF- polyarthritis, extended oligoarthritis from 2 years of age, psoriatic arthritis and ERA from 12 years of age. · 17/01/2013 - adalimumab - treatment of active polyarticular juvenile idiopathic arthritis in the paediatric population aged from 2 to 4 years old. · 25/04/2013 - tocilizumab - treatment of polyarthritis (RF+, RF- and extended oligoarthritis) from 2 years old (EC decision pending at the time of abstract submission). 4. A network of paediatric research networks Enpr-EMA works by fostering collaboration from within and outside the European Union (EU), including between members, patients associations, academia and the pharmaceutical industry.) PRINTO and JSWG of PRES are members of Enpr-EMA. 5. Expert meetings at EMA: Paediatric rheumatology (2009, 2010), Gastroenterology and rheumatology (2010). 6. Development of scientific guidelines (JIA, SLE, GIOP). 7. Pharmacovigilance ENCEPP - (PharmaChild protocol agreed).
Highlights
PReS13-SPK-1182: Six years of eu paediatric regulation - what was achieved for paediatric rheumatology
EU Paediatric Regulation was adopted by the European Parliament and the Council in December 2006
First meeting of the Paediatric Committee took place in July 2007
Summary
PReS13-SPK-1182: Six years of eu paediatric regulation - what was achieved for paediatric rheumatology
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
